Manpower Outsourcing Revenue Increased 62.4% to US$15.6 Million; Integrated Facility Management Revenue Increased 11.1% to US$16.1 Million Net Loss Narrowed 13.8% Year Over Year Working Capital Improved to US$11.9 Million from a Deficit of US$1.7 Million at Year-End 2025; Total Liabilities Reduced 39% SINGAPORE, Sept. 24, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (Nasdaq: YFOR) (“YYForce” or the “Company,” formerly YY Group Holding Limited (Nasdaq: YYGH)), an AI-enabled workforce management platform and integrated facility management (IFM) provider operating across Asia and beyond, today announced its unaudited financial results for the six months ended June 30, 2026. YYForce reported first-half 2026 revenue of approximately US$32.7 million, an increase of 26.8% from US$25.8 million for the corresponding period...

ISSAQUAH, Wash., Sept. 24, 2026 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the 16-week fourth quarter and the 52-week fiscal year ended August 30, 2026. Net sales for the quarter increased 11.2 percent, to $93.9 billion, from $84.4 billion last year. Net sales for the fiscal year increased 10.1 percent, to $297.2 billion, from $269.9 billion last year. Comparable sales for the fourth quarter and fiscal year were as follows:  16 Weeks   16 Weeks   52 Weeks   52 Weeks      Adjusted*       Adjusted*U.S. 10.7%   7.2%   8.2%   6.6%Canada 5.0%   4.6%   7.8%   6.7%Other International 7.0%   6.2%   9.8%   6.5%               Total Company 9.4%   6.7%   8.4%   6.6%               Digitally-Enabled 19.5%   19.8%   20.9%   20.7%*Excluding...

Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation Strengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029 Acceptable safety profile and promising initial efficacy responses observed in Johnson & Johnson-led Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in Stage 3 unresectable NSCLC U.S. FDA clearance for protocol amendment to the Johnson & Johnson-led Phase 3 NANORAY-312 study evaluating JNJ-1900 (NBTXR3) in locally advanced platinum ineligible head and neck cancer €110.9 million in cash and cash equivalents...

REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026. Tumor HIupLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumor HI, is ongoing.Enrollment is in progress and topline results are expected before the end of 2026.In June 2026, the Company shared positive interim data from the upLIFT study, announcing that of the 8 participants enrolled, 6 had already met the responder criterion for the study’s primary endpoint within the 8-week pivotal treatment...

ROBERTET GROUP – INTERIM CONSOLIDATED FINANCIAL STATEMENTS – HALF-YEAR 2026AttachmentROBERTET-RFS-EN_2026

ABC Arbitrage  Release of the half-year financial report as of June 30, 2026ABC arbitrage announces that as of today its financial report for the first half of 2026 has been publicly released and filed with the Autorité des Marchés Financiers (AMF).  This document includes the following parts:The half-year management report The half-year consolidated financial statements The statutory auditors’ report Statement by the person responsible for the financial reportThe annual financial report can be consulted on the Group website at: abc-arbitrage.com, in the “Shareholders” page, heading Financial information / Financial reports.Contacts: abc-arbitrage.comShareholders contact: actionnaires@abc-arbitrage.comPress contact: VERBATEE / v.sabineu@verbatee.com EURONEXT Paris – Compartiment BISIN : FR0004040608Reuters ...

2026 Half-Year Results and Business Update myvac® – Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturing TG4050 – First Individualized Neoantigen Therapeutic Vaccine (INTV) from the myvac® platform advancing in resected HNSCC1Randomized Phase 1 data published in Nature Communications; Sustained 100% disease-free survival (DFS) after more than 3 years of follow-up, showing durable clinical outcomes and potential to prevent cancer recurrence Randomized Phase 2 recruitment completed, trial is ongoing with topline results expected in Q1 2028 Preparing for potential pivotal trial in HNSCC with cell-line manufacturingTG4070 – Second novel myvac®-based INTV in early-stage NSCLC2, with potential to be applied across multiple early-stage solid tumor typesLeverages...

2026 Half-Year Financial ReportAttachmentTransgene_HYR26_EN

Strasbourg, September 24, 2026, 5:45 pm CET TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2026. The document is available on the Company’s website: www.transgene.fr, in the “Investors/Financial information” section. This report comprises the following documents:2026 half-year financial statements; Half-year management report; Statutory Auditors’ report on the 2026 half-year financial statements; Declaration by the person responsible for this half-year financial report.ContactsMedia: Caroline Tosch Corporate and Scientific Communications Manager +33 3 68 33 27 38 communication@transgene.fr Investors & Analysts: Lucie Larguier Chief Financial Officer+33 3 88 27 91 00 investorrelations@transgene.fr...

RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2026Revenue up 4.5% to 84.5 M€Proprietary products account for 37% of revenue 46% of revenue generated outside FranceFree cash flow of €4 million after investments Net debt of €147.4 million, including the EB Development shareholder loan Acquisition of CareDx’s Lab Solutions business finalized on June 30, 2026Paris, September 24, 2026 – 17h40 – Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, today presents its consolidated results as of June 30, 2026, prepared in accordance with French standards and approved by the company’s Board of Directors at its meeting on September 24, 2026. Eurobio Scientific’s results as of June 30, 2026 show growth in business activity. Revenue reached €84.5 million, up 4.5%, driven...